BE550847A - - Google Patents
Info
- Publication number
- BE550847A BE550847A BE550847DA BE550847A BE 550847 A BE550847 A BE 550847A BE 550847D A BE550847D A BE 550847DA BE 550847 A BE550847 A BE 550847A
- Authority
- BE
- Belgium
- Prior art keywords
- solution
- thiamine
- thiourea
- chloride
- phenol
- Prior art date
Links
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea group Chemical group NC(=S)N UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 claims description 16
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 claims description 11
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 claims description 11
- 229960003495 thiamine Drugs 0.000 claims description 11
- 235000019157 thiamine Nutrition 0.000 claims description 11
- 239000011721 thiamine Substances 0.000 claims description 11
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 8
- 150000002148 esters Chemical class 0.000 claims description 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 7
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims description 6
- 239000003223 protective agent Substances 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 239000000243 solution Substances 0.000 description 19
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 7
- 239000012154 double-distilled water Substances 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 238000000354 decomposition reaction Methods 0.000 description 4
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 4
- 235000017557 sodium bicarbonate Nutrition 0.000 description 4
- -1 ester chloride Chemical class 0.000 description 3
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 150000003585 thioureas Chemical class 0.000 description 2
- 241000551546 Minerva Species 0.000 description 1
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A61K31/51—Thiamines, e.g. vitamin B1
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BE550847A true BE550847A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) |
Family
ID=176578
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BE550847D BE550847A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) |
Country Status (1)
| Country | Link |
|---|---|
| BE (1) | BE550847A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) |
-
0
- BE BE550847D patent/BE550847A/fr unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0316993B1 (fr) | Compositions pharmaceutiques contenant un dérivé de l'acide 3-hydroxybutanoique choisi parmi les oligomères de cet acide et les esters de cet acide ou de ces oligomères avec du 1,3-butanediol | |
| CH662272A5 (fr) | Composition pharmaceutique contenant de la ranitidine. | |
| EP0287488A1 (fr) | Médicament, produit diététique et produit d'hygiène sous la forme d'une composition pulvérulente obtenue par adsorption de principes actifs sur un sucre à dissolution rapide et procédé d'obtention de ladite composition | |
| FR2688405A1 (fr) | Procede d'une preparation d'une solution medicinale stable pour voie orale a liberation controlee, a base d'un beta-bloquant, et composition pharmaceutique a base d'un beta-bloquant. | |
| BE1007194A3 (fr) | Composition pharmaceutique ayant une activite analgesique. | |
| BE550847A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | ||
| FR2681863A1 (fr) | Solution de sparfloxacine sa preparation et sel la constituant. | |
| RU2103999C1 (ru) | Способ лечения алкоголизма | |
| BE1005196A0 (fr) | Compositions pharmaceutiques aqueuses de cromoglycate sodique. | |
| US4767783A (en) | Gallstone dissolver | |
| EP0086705A1 (fr) | Solution aqueuse d'acide ursodésoxycholique à usages thérapeutiques, son procédé de préparation et application au traitement des lithiases biliaires | |
| Swell et al. | Influence of bile acids on biliary lipid excretion in man: Implications in gallstone formation | |
| FR2561104A1 (fr) | Etoposide sous forme de dose destinee a une utilisation orale | |
| EP0012640A1 (fr) | Procédé de purification de l'acide chénodésoxycholique et produits obtenus par ce procédé | |
| EP0920320A2 (fr) | Composition pharmaceutique injectable contenant l'acide ursodesoxycholique ou l'acide tauroursodesoxycholique, une base forte et du trometamol | |
| FR2461463A1 (fr) | Procede de preparation d'eaux minerales ferrugineuses, eaux minerales obtenues par ce procede et leurs applications therapeutiques | |
| FR2624736A1 (fr) | Nouvelles compositions pharmaceutiques dispersibles dans l'eau a base d'ornidazole | |
| CN111057130A (zh) | 一种高纯度的米卡芬净或其盐及其制备方法和用途 | |
| FR2622800A1 (fr) | Procede de preparation d'un produit de lutte contre des affections virales en particulier des affections virales cutaneo-muqueuses,compositions pharmaceutiques et medicaments obtenus a partir de ce procede | |
| BE897980A (fr) | Procede pour la preparation d'une solution a usage pharmaceutique contenant un nouveau complexe mixte polynuclaire de fer (iii) comme ingredient actif | |
| Magendie | Formulary for the preparation and employment of several new remedies, tr., with an appendix, by J. Houlton | |
| FR2510580A1 (fr) | Nouvel heteroside flavonique extrait du gnidia kraussiana, utilisable dans la sclerose en plaques, les affections autoimmunes et certaines proliferations malignes | |
| FR2461498A1 (fr) | Procede de preparation de solutions concentrees d'amygdaline sous sa forme naturelle, et produits ainsi obtenus | |
| WO2010119305A1 (en) | Using of quaternary ammonium compounds in dissolving of latanoprost | |
| NO144094B (no) | Fremgangsmaate til fremstilling av smertestillende middel |